Results: A total of 9724 liver transplant recipients were included. Patients receiving a graft procured from a donor older than 60 years (adjusted hazard ratio (HR) 1⋅38, 95 per cent c.i. 1⋅10 to 1⋅73; P = 0⋅006), a donor with a history of diabetes (adjusted HR 1⋅43, 1⋅11 to 1⋅83; P = 0⋅006) and a donor with a body mass index of 35 kg/m 2 or more (adjusted HR 1⋅36, 1⋅04 to 1⋅77; P = 0⋅023) had an increased rate of post-transplant HCC recurrence. In 3007 patients with documented steatosis, severe graft steatosis (more than 60 per cent) was also linked to an increased risk of recurrence (adjusted HR 1⋅65, 1⋅03 to 2⋅64; P = 0⋅037). Recipients of organs from donation after cardiac death donors with prolonged warm ischaemia had higher recurrence rates (adjusted HR 4⋅26, 1⋅20 to 15⋅1; P = 0⋅025).
Introduction
Hepatocellular carcinoma (HCC) is a common indication for liver transplantation and, despite careful patient selection, 8-15 per cent of patients experience post-transplant HCC recurrence 1 . Candidate selection and organ allocation policy are key issues in liver transplantation for oncological indications, accounting for their continuous refinements in the literature 2 . Many studies have shown that the Milan criteria were too restrictive and confined to information regarding tumour morphology; several alternative scores 2 -4 have been developed since the landmark study by Mazzaferro and colleagues 5 . There is compelling evidence that the use of α-fetoprotein (AFP) in selection criteria allows a more accurate prediction of the risk of both waiting list drop-out 6 and post-transplant HCC recurrence 7 .
Besides primary tumour characteristics, liver graft quality also deserves attention, considering the susceptibility to parenchymal damage of marginal grafts, and the interactions between cancer cells and tumour microenvironment 8 . Moreover, recent findings 9 that liver parenchymal abnormalities independently alter the oncological outcome in the setting of liver resection may also be relevant in the context of liver transplantation. Regeneration of a liver graft in the presence of cancer constitutes a theoretical risk of fostering tumour cell proliferation 10, 11 . In addition, preclinical studies have outlined the link between ischaemia-reperfusion and liver tumour growth 12 -14 . Clinical data regarding the impact of donor characteristics on post-transplant HCC recurrence are still limited. Some studies have shown that donation after cardiac death (DCD) synergistically increases post-transplant mortality in patients with HCC compared with that in patients without HCC 15 . Moreover, Nagai and co-workers 16 have shown that prolonged cold and warm ischaemia times are linked to increased HCC recurrence rates following liver transplantation. Recently, it was shown 17 that identification of HCC recurrence in the US Organ Procurement and Transplantation Network (OPTN) database was feasible and valid. Based on these observations, the aim of the present study was to analyse the American Scientific Registry of Transplant Recipients (SRTR) to evaluate the impact of donor characteristics and liver graft quality on the risk of post-transplant HCC recurrence.
Methods
Data from the SRTR were used. The study population comprised adult patients with HCC who received a first liver transplantation between January 2004 and September 2011, having fulfilled the exception criteria for liver transplant eligibility. Retrieved characteristics of the population were age, sex, body mass index (BMI), primary tumour and underlying diagnosis of liver disease (including HCC), time spent on the waiting list, date of transplantation, and transplant centre.
In patients with multiple HCC nodules, total tumour volume (TTV) was calculated by summing the radiological (CT) volumes of each independent tumour. Tumour size was calculated as the volume of a sphere (4/3 × π × (tumour radius) 3 ). A composite measure of tumour size and behaviour, the TTV/AFP score, was used to adjust for tumour characteristics in the final model 2 . Briefly, this score combines radiological and biological characteristics of the tumour(s) and dichotomizes patients into the following two categories: TTV of 115 cm 3 or less and AFP blood level of 400 ng/ml or less (low risk); and TTV greater than 115 cm 3 or AFP blood level above 400 ng/ml (high risk).
Potential predictors of post-transplant HCC recurrence were: donor age, sex, BMI, donor diabetes, smoking history, DCD (versus donation after brain death), type of graft (whole versus split/partial), cold ischaemia time, primary warm ischaemia time among DCD donors, allocation policy (a variable that discriminates between organs used at the local level and those exported at regional or national level), and immunosuppressive drugs (sirolimus versus other). The 19 , as well as to measure the impact of potential predictors in the univariable analysis. To determine the corrected impact of donor characteristics on risk of recurrence, multivariable Cox proportional hazard ratios (HRs) were calculated, adjusting for the following confounders: tumour characteristics (given by the TTV/AFP score) and recipient characteristics (age, sex, BMI, underlying liver disease, date of transplantation, and time spent on the waiting list). As HCC-bearing liver transplant candidates underwent repeated assessments, only the most recent values for AFP and tumour volume were used. In the Cox model the analysis was stratified by transplant centre, whereas in the competing risk model the analysis was adjusted for transplant centre, because stratification is not feasible in multivariable competing risk analyses. The proportional hazards assumption was tested using Schoenfeld's residuals 20 . In addition, a multivariable competing risk regression based on the method by Fine and Gray 21 was carried out. For all analyses a two-tailed P ≤ 0⋅050 was considered significant. Statistical analyses were performed using Stata ® version 11 (StataCorp LP, College Station, Texas, USA) and the package cmprsk for R version 3⋅0⋅1 (R Foundation for Statistical Computing, Vienna, Austria). (i.q.r. 1⋅3-9⋅8) months and median length of follow-up was 3 (2-7) years. Other baseline recipient, tumour and donor characteristics are shown in Table 1 .
Results

Between
Donor-and graft-related factors and the risk of HCC recurrence
First, to rule out the potential bias that liver grafts of increasingly poor quality were allocated to recipients with more aggressive tumours, tumour burden (as assessed by most recent AFP level and TTV) and donor characteristics were compared. There was no evidence that the approach of using suboptimal grafts in oncologically suboptimal recipients was reflected in the present data set. Moreover, there was no association between DRI and tumour characteristics, as assessed by one-way ANOVA with Bonferroni's correction through several categories of AFP (P = 0⋅174) and tumour volume (P = 0⋅888) ( Table S1 , supporting information). Next, Kaplan-Meier function and a competing risk model were used to calculate HCC recurrence rates. In the whole population (9724 patients), the cumulative recurrence rates at 1, 3 and 5 years after transplant were 2⋅1 (95 per cent c.i. 1⋅8 to 2⋅4), 5⋅8 (5⋅3 to 6⋅3) and 7⋅8 (7⋅2 to 8⋅5) per cent respectively. After taking competing events into account, these rates were slightly lower at 2⋅0 (1⋅7 to 2⋅2), 5⋅3 (4⋅8 to 5⋅8) and 6⋅9 (6⋅3 to 7⋅5) per cent respectively (Fig. 1) donors with a history of diabetes (P = 0⋅004), with a BMI of 35 kg/m 2 or above (P = 0⋅030) and donors older than 60 years (P = 0⋅008) had a higher post-transplant recurrence risk ( Fig. 2 ; Table S2 , supporting information). Liver grafts with a sharing allocation policy also showed increased recurrence rates (P = 0⋅001). DCD transplantation did not significantly impact on outcome (P = 0⋅526), nor did cold ischaemia time (P = 0⋅155). Corresponding results from the non-competing risk univariable Cox model were similar (data not shown).
To adjust for confounders, a multivariable Cox proportional hazards model was fitted, stratifying by transplant centre. There was strong evidence that tumour characteristics, as assessed by the TTV/AFP score, were the main predictors of tumour recurrence (HR 3⋅11, 95 per cent c.i. 2⋅45 to 3⋅93; P < 0⋅001). The adjusted effects of donor-related factors on post-transplant HCC recurrence are shown in Table 2 . Donor history of diabetes, raised donor age (greater than 60 years) and increased donor BMI (35 kg/m 2 or above) were independently associated with increased HCC recurrence rates. When donor BMI was analysed as a continuous co-variable, the adjusted HR of 1⋅02 (1⋅01 to 1⋅03; P = 0⋅023) indicated that a 10-kg/m 2 rise in donor BMI increased the risk of cancer relapse by 20 per cent. After adjustment, organ allocation policy was no longer significantly associated with recurrence (P = 0⋅072). The test of proportional hazards assumption according to Schoenfeld's residuals showed no evidence to reject the final model (P > 0⋅100), and there was no statistical interaction between donor and tumour characteristics (the TTV/AFP score) (P value for interaction: donor diabetes, 0⋅852; donor BMI, 0⋅593; and donor age, 0⋅415). Use of a multivariable competing risk model did not alter the magnitudes of effect found in the Cox regression, nor their significance ( Table 2) . Finally, because factors such as diabetes and increasing BMI commonly underlie hepatic steatosis 22 , the impact of graft steatosis on the oncological outcomes of liver transplantation for HCC was assessed. A sensitivity analysis was performed including only patients with available information regarding donor liver steatosis (3007 patients). In both the univariable and multivariable analyses, only severe graft steatosis (greater than 60 per cent) was independently associated with increased post-transplant HCC recurrence (adjusted HR 1⋅65, 95 per cent c.i. 1⋅03 to 2⋅64; P = 0⋅037) (Fig. 3) .When restricting the analysis to patients receiving a graft from a DCD donor, primary (donor) warm ischaemia, as a continuous co-variable, had no impact on HCC recurrence (P = 0⋅179). In contrast, when dichotomizing between donors with warm ischaemia longer than the 75th percentile (19 min), donor warm ischaemia was associated with HCC recurrence in both the univariable analysis (P = 0⋅036) and multivariable analysis (adjusted HR 4⋅26, 1⋅20 to 15⋅1; P = 0⋅025) (Fig. 3) .
Discussion
This study identified donor characteristics that were independently associated with the risk of HCC recurrence after liver transplantation and that were readily available at the time of organ allocation. The present findings confirm that the risk of post-liver transplant HCC recurrence is determined predominantly by recipient's tumour characteristics 5 , given the markedly increased HR for recurrence in patients with a raised TTV/AFP score (TTV above 115 cm 3 and/or AFP blood level greater than 400 ng/ml). However, in addition to tumour-related factors, there is growing evidence that parenchymal damage due to ischaemia-reperfusion and donor characteristics per se may also impact on liver cancer growth 13 . Recently, Sharma and colleagues 23 showed that donor age was an independent predictor of post-transplant HCC recurrence. Consistent with these findings, the University of California, San Francisco team 24 recently showed that donor age (as well as organ sharing beyond local use) impacted on the risk of post-transplant HCC recurrence. Using the same methodology, but going one step further, the present study reveals that liver grafts procured from donors with raised BMI, with a history of diabetes, and with severe graft steatosis also indicate a higher recurrence risk, even after allowing for tumour and recipient characteristics, underlying liver disease, time spent on the waiting list and transplant centre.
Importantly, these findings do not seem to be confounded by the common practice of allocating increasingly marginal liver grafts to patients with more advanced tumours.
Donor diabetes and increasing donor BMI are common causes of hepatic steatosis, and accumulating evidence indicates that diabetes, increasing BMI and non-alcoholic fatty liver disease are associated with an increased incidence of primary liver cancer. In addition, although not uniformly 25 , previous data from both experimental 26 and clinical 9 settings have shown that fatty livers are prone to cancer growth and recurrence after oncological liver surgery. Recipient obesity has also been reported 27 to be associated with an earlier and increased risk of HCC recurrence after liver transplantation. In this regard, steatosis may be related to increased post-transplant cancer recurrence through several mechanisms. Fatty livers show alterations in mitochondrial metabolism and increased production of insulin-like growth factor 1, which promotes cell growth and proliferation, and inhibits apoptosis 28, 29 . Lipid toxicity and increased oxidative stress in the steatotic liver foster repetitive cycles of apoptosis and regeneration/proliferation, which may lead to aberrant DNA repair and tumour initiation 30 . In addition, reduced expression of the tumour suppressor gene PTEN in fatty livers has been shown to favour hepatic tumorigenesis 31 . Of note, although severe steatosis was found to be a risk factor for post-transplant HCC recurrence, the present study does not discriminate between the types of steatosis, and studies evaluating whether microsteatosis and macrosteatosis have differential effects on HCC recurrence are needed.
Among livers obtained from DCD donors, those with prolonged warm ischaemia showed an increased HCC recurrence risk (adjusted P = 0⋅025). This is in line with preclinical data 12 -14 showing that warm ischaemia-reperfusion fosters cancer cell invasiveness. In particular, the present authors 32 have shown that prerecovery graft reperfusion decreases HCC recurrence after liver transplantation in rats. In contrast there was a lack of association with cold ischaemia; this could be related either to the relatively low cold ischaemia time in the present population, leaving only few patients with upper values, or to a true lack of association between cold ischaemia and HCC recurrence.
In their validation of post-transplant HCC recurrence in the OPTN database, Samoylova et al. 17 identified increasing DRI as a risk factor for cancer relapse. The DRI is a composite measure integrating, in a simple algebraic formula, various donor characteristics such as donor age, race, cause of death and cold ischaemia time, amongst others 18 . The DRI provides valid information on the process of liver graft acceptance by predicting liver graft failure. However, as the purpose of the present analysis was to assess whether specific donor-related factors were associated with HCC recurrence, the use of a composite measure such as the DRI was deemed inappropriate, as it would have led to loss of information.
There are shortcomings to this study. First, information regarding microvascular invasion, satellite lesions and tumour differentiation were not available in the SRTR. Second, although the low 5-year recurrence rate could be explained by a combination of the strict selection policy applied in most US centres and the use of a competing risk model, it cannot be excluded that some patients with recurrence might have been missed. Potentially missing recurrences would challenge the present results only if donor factors truly influenced patient follow-up and the way recurrence was recorded after transplantation, which is an unlikely scenario. Third, because HCC recurrence was recorded either at the time of recurrence or at the time of death from recurrence, cumulative recurrence curves may display events in a delayed fashion. Of note, the distribution of patients with a recurrence identified at the time of recurrence or at the time of death from recurrence was similar among study groups, and did not impact on the outcome. Moreover, late HCC recurrence is not rare, and in a recent study 33 41 per cent of patients with recurrence developed the recurrence more than 24 months after transplantation. Finally, recurrent HCC may occur in locations other than the liver graft; although both extrahepatic and intrahepatic recurrences were included in the present study, a separate assessment of extrahepatic recurrence could not be made. It could therefore be speculated that some liver grafts may release soluble factors that promote remote cancer cell implantation and growth.
